Neurocrine Biosciences
NBIX
NBIX
302 hedge funds and large institutions have $7.51B invested in Neurocrine Biosciences in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 119 increasing their positions, 103 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
4% less capital invested
Capital invested by funds: $7.8B → $7.51B (-$289M)
7% less funds holding
Funds holding: 325 → 302 (-23)
30% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 53
Holders
302
Holding in Top 10
8
Calls
$73.7M
Puts
$48.6M
Top Buyers
| 1 | +$298M | |
| 2 | +$102M | |
| 3 | +$72.2M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$64.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$62.1M |
Top Sellers
| 1 | -$104M | |
| 2 | -$54.4M | |
| 3 | -$51.2M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$49.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$33M |